HSBC trading unit hit by $355m of XVA costs in H1
Adverse adjustments to the valuation of non-cleared derivatives (XVAs) at HSBC continued to sap earnings over the three months to end-June. Over the first six months of the year, credit valuation adjustments (CVA) and funding valuation adjustments (FVA) have lopped a combined $355 million off of income.
The hit was recorded at the UK firm’s global banking and markets (GB&M) division, and was equivalent in size to 4% of first-half revenues. Over the half-year to June 2019, CVA and FVA
Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.
To access these options, along with all other subscription benefits, please contact [email protected] or view our subscription options here: http://subscriptions.risk.net/subscribe
You are currently unable to print this content. Please contact [email protected] to find out more.
You are currently unable to copy this content. Please contact [email protected] to find out more.
Copyright Infopro Digital Limited. All rights reserved.
You may share this content using our article tools. Printing this content is for the sole use of the Authorised User (named subscriber), as outlined in our terms and conditions - https://www.infopro-insight.com/terms-conditions/insight-subscriptions/
If you would like to purchase additional rights please email [email protected]
Copyright Infopro Digital Limited. All rights reserved.
You may share this content using our article tools. Copying this content is for the sole use of the Authorised User (named subscriber), as outlined in our terms and conditions - https://www.infopro-insight.com/terms-conditions/insight-subscriptions/
If you would like to purchase additional rights please email [email protected]
More on Risk Quantum
Derivatives
SEC’s Gensler takes aim at Bloomberg’s BSBY index
Credit sensitive SOFR alternative has “many of the same flaws as Libor”, regulator says
Receive this by email